利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

43 条记录 (耗时 0.019 秒)

    GDF15 MARKER PANELS FOR EARLY DETECTION OF SEPSIS
    1.
    发明申请
    GDF15 MARKER PANELS FOR EARLY DETECTION OF SEPSIS 审中-公开

    公开(公告)号：WO2022229415A2

    公开(公告)日：2022-11-03

    申请号：PCT/EP2022/061543

    申请日：2022-04-29

    申请人： F. HOFFMANN-LA ROCHE AG ,  ROCHE DIAGNOSTICS GMBH ,  ROCHE DIAGNOSTICS OPERATIONS, INC.

    发明人： GRUENEWALD, Felix ,  JEGER, Victor Johann Raul ,  KLAMMER, Martin ,  SCHUETZ, Philipp ,  VON HOLTEY, Maria ,  WEBER, Stephen ,  WEGMEYER, Heike ,  WIENHUES-THELEN, Ursula-Henrike

    IPC分类号： G01N33/68 ,  G01N2800/26 ,  G01N2800/50 ,  G01N33/6863 ,  G01N33/6893

    摘要： The present invention relates to a method for assessing a subject with suspected infection comprising the steps of determining the amount of a first biomarker in a sample of the subject, said first biomarker being GDF-15, determining the amount of a second biomarker in a sample of the subject, wherein said second biomarker is selected from the group consisting of: sFLT1, Cystatin C, IGFBP-7, Bilirubin, ESM-1, sTREM-1, Procalcitonin, cardiac Troponin, BNP-type peptide, Alanine aminotransferase, and Aspartate aminotransferase, comparing the amounts of the biomarkers to references for said biomarkers and/or calculating a score for assessing the subject with suspected infection based on the amounts of the biomarkers, and assessing said subject based on the comparison and/or the calculation. The invention also relates to the use of a first biomarker being GDF-15 and a second biomarker selected from the group consisting of sFLT1, Cystatin C, IGFBP-7, Bilirubin, ESM-1, sTREM-1, Procalcitonin, cardiac Troponin, BNP-type peptide, Alanine aminotransferase, and Aspartate aminotransferase or a detection agent specifically binding to said first biomarker and a detection agent specifically binding to said second biomarker for assessing a subject with suspected infection. Moreover, the invention further relates to a computer-implemented method for assessing a subject with suspected infection and a device and a kit for assessing a subject with suspected infection.

    RENAL INSUFFICIENCY PREDICTION AND USES THEREOF
    6.
    发明申请
    RENAL INSUFFICIENCY PREDICTION AND USES THEREOF 审中-公开

    公开(公告)号：WO2022266031A2

    公开(公告)日：2022-12-22

    申请号：PCT/US2022/033333

    申请日：2022-06-14

    申请人： SOMALOGIC OPERATING CO., INC.

    发明人： SAMPSON, Laura ,  SIMPSON, Missy ,  HAGAR, Yolanda ,  OSTROFF, Rachel Marie

    IPC分类号： G01N33/68 ,  G01N2333/78 ,  G01N2800/347 ,  G01N2800/50 ,  G01N33/6893

    摘要： The present disclosure includes biomarkers, methods, devices, reagents, systems, and kits for the evaluation of risk of renal insufficiency within a specified timeframe, for example 4 years. In one aspect, the disclosure provides biomarkers that can be used alone or in various combinations to evaluate risk of renal insufficiency within 4 years. In another aspect, methods are provided for evaluating risk of renal insufficiency within 4 years in an individual, where the methods include detecting, in a biological sample from an individual, at least one biomarker value corresponding to at least one biomarker selected from the group of biomarkers provided in Table 8.

    PRESEPSIN MARKER PANELS FOR EARLY DETECTION OF SEPSIS
    8.
    发明申请
    PRESEPSIN MARKER PANELS FOR EARLY DETECTION OF SEPSIS 审中-公开

    公开(公告)号：WO2022229442A2

    公开(公告)日：2022-11-03

    申请号：PCT/EP2022/061587

    申请日：2022-04-29

    申请人： F. HOFFMANN-LA ROCHE AG ,  ROCHE DIAGNOSTICS GMBH ,  ROCHE DIAGNOSTICS OPERATIONS, INC. ,  MOCHIDA PHARMACEUTICAL CO., LTD.

    发明人： GRUENEWALD, Felix ,  JEGER, Victor Johann Raul ,  KLAMMER, Martin ,  SCHUETZ, Philipp ,  VON HOLTEY, Maria ,  WEBER, Stephen ,  WEGMEYER, Heike ,  WIENHUES-THELEN, Ursula-Henrike

    IPC分类号： G01N33/68 ,  G01N2333/70596 ,  G01N2800/26 ,  G01N2800/50 ,  G01N33/6893

    摘要： The present invention concerns the field of diagnostics. Specifically, it relates to a method for assessing a subject with suspected infection comprising the steps of determining the amount of a first biomarker in a sample of the subject, said first biomarker being Presepsin, determining the amount of a second biomarker in a sample of the subject, wherein said second biomarker is selected from the group consisting of: GDF-15, Creatinine, sF1t1, IGFBP7, sTREM1, Cystatin C and PSP (Pancreatic Stone Protein), comparing the amounts of the biomarkers to references for said biomarkers and/or calculating a score for assessing the subject with suspected infection based on the amounts of the biomarkers, and assessing said subject based on the comparison and/or the calculation. The invention also relates to the use of a first biomarker being Presepsin and a second biomarker selected from the group consisting of: GDF-15, Creatinine, sF1t1, IGFBP7, sTREM1, Cystatin C and PSP (Pancreatic Stone Protein), or a detection agent specifically binding to said first biomarker and a detection agent specifically binding to said second biomarker for assessing a subject with suspected infection. Moreover, the invention further relates to a computer-implemented method for assessing a subject with suspected infection and a device and a kit for assessing a subject with suspected infection.

    METHODS FOR TREATING OCULAR DISEASES
    10.
    发明申请
    METHODS FOR TREATING OCULAR DISEASES 审中-公开

    公开(公告)号：WO2022201084A1

    公开(公告)日：2022-09-29

    申请号：PCT/IB2022/052692

    申请日：2022-03-24

    申请人： NOVARTIS AG

    发明人： EHLERS, Justis P. ,  SARICI, Kubra ,  SRIVASTAVA, Sunil ,  ZAHID, Robert

    IPC分类号： A61K39/395 ,  A61P27/02 ,  C07K16/22 ,  A61K2039/505 ,  A61K2039/54 ,  A61K2039/545 ,  A61K2039/55 ,  A61K39/3955 ,  C07K2317/76 ,  G01N2800/16 ,  G01N2800/50 ,  G01N2800/52

    摘要： The invention relates to methods for treating ocular disease with a VEGF antagonist. In particular, the invention relates to methods for treating ocular disease, the method comprising selectively administering a VEGF antagonist to a subject in need thereof on the basis of said subject not having a preretinal or vitreous hyperreflective foci formation. The invention further relates to methods for determining whether a subject with ocular disease should be treated with a VEGF antagonist, methods of predicting the likelihood that a subject having ocular disease will develop intraocular inflammation in response to a treatment with a VEGF antagonist, and methods for producing a transmittable form of information for determining whether a subject with ocular disease should be treated with a VEGF antagonist or for predicting whether a subject with ocular disease may develop intraocular inflammation in response to a treatment with a VEGF antagonist.